Literature DB >> 19035983

The accuracy of the FIB-4 index for the diagnosis of mild fibrosis in chronic hepatitis B.

V Mallet1, V Dhalluin-Venier, C Roussin, M Bourliere, M E Pettinelli, C Giry, A Vallet-Pichard, H Fontaine, S Pol.   

Abstract

BACKGROUND: The Fib-4 index is a simple and inexpensive biomarker to delineate liver fibrosis in chronic hepatitis C. AIM: To assess the accuracy of the FIB-4 index in chronic hepatitis B.
METHODS: We compared the FIB-4 index with 138 synchronous liver biopsies and with 372 synchronous FibroTest performed either in France or in an endemic area (Mayotte, an overseas collectivity of France).
RESULTS: The FIB-4 index allowed the correct identification of patients with nil-to-moderate fibrosis with an area under the receiving operating characteristic curve of 0.81 (P < 0.001), increasing as a function of the length of the liver biopsy (up to 0.94 for liver biopsies >or=20 mm). A cut-off value <or=1.45 differentiated moderate fibrosis from severe fibrosis with a negative predictive value of 86%, a sensitivity of 71.1% and a specificity of 73.1%. Beyond 1.45, the FIB-4 index was not informative. The FIB-4 index was more precise than the AST-to-platelet ratio index and correlated with the FibroTest in 89% of the cases (kappa = 0.27, P < 0.001) to exclude severe fibrosis.
CONCLUSION: The FIB-4 index is a simple, accurate and inexpensive method to exclude significant liver fibrosis in chronic hepatitis B, a major advantage in HBV-endemic developing countries.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19035983     DOI: 10.1111/j.1365-2036.2008.03895.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  37 in total

Review 1.  Targeting Hepatic Fibrosis in Autoimmune Hepatitis.

Authors:  Aldo J Montano-Loza; Ragesh B Thandassery; Albert J Czaja
Journal:  Dig Dis Sci       Date:  2016-07-19       Impact factor: 3.199

2.  Noninvasive markers for staging fibrosis in chronic delta hepatitis.

Authors:  V Takyar; P Surana; D E Kleiner; K Wilkins; J H Hoofnagle; T J Liang; T Heller; C Koh
Journal:  Aliment Pharmacol Ther       Date:  2016-11-04       Impact factor: 8.171

3.  Changes of FibroScan, APRI, and FIB-4 in chronic hepatitis B patients with significant liver histological changes receiving 3-year entecavir therapy.

Authors:  Qiang Li; Liang Chen; Yu Zhou
Journal:  Clin Exp Med       Date:  2018-01-19       Impact factor: 3.984

4.  Change in fibrosis score as a predictor of mortality among HIV-infected patients with viral hepatitis.

Authors:  Mamta K Jain; Emmanuel Seremba; Rafia Bhore; Doan Dao; Reeti Joshi; Nahid Attar; He-Jun Yuan; William M Lee
Journal:  AIDS Patient Care STDS       Date:  2012-01-12       Impact factor: 5.078

Review 5.  Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection.

Authors:  Pathik Parikh; John D Ryan; Emmanuel A Tsochatzis
Journal:  Ann Transl Med       Date:  2017-02

6.  Predictive value of FIB-4 and APRI versus METAVIR on sustained virologic response in genotype 1 hepatitis C patients.

Authors:  Peter Ferenci; Rodrigo Aires; Kimberly L Beavers; Manuela Curescu; Paulo R Abrão Ferreira; Michael Gschwantler; Stefan Ion; Dominique Larrey; Mojca Maticic; Massimo Puoti; János Schuller; Istvan Tornai; Anna Tusnádi; Diethelm Messinger; Fernando Tatsch; Andrzej Horban
Journal:  Hepatol Int       Date:  2013-11-22       Impact factor: 6.047

7.  Association of hepatitis C with markers of hemostasis in HIV-infected and uninfected women in the women's interagency HIV study (WIHS).

Authors:  Elizabeth M Kiefer; Qiuhu Shi; Donald R Hoover; Robert Kaplan; Russell Tracy; Michael Augenbraun; Chenglong Liu; Marek Nowicki; Phyllis C Tien; Mardge Cohen; Elizabeth T Golub; Kathryn Anastos
Journal:  J Acquir Immune Defic Syndr       Date:  2013-03-01       Impact factor: 3.731

Review 8.  Noninvasive models for assessment of liver fibrosis in patients with chronic hepatitis B virus infection.

Authors:  Da-Wu Zeng; Jing Dong; Yu-Rui Liu; Jia-Ji Jiang; Yue-Yong Zhu
Journal:  World J Gastroenterol       Date:  2016-08-07       Impact factor: 5.742

9.  Non-invasive assessment of liver fibrosis in chronic liver diseases: implementation in clinical practice and decisional algorithms.

Authors:  Giada Sebastiani
Journal:  World J Gastroenterol       Date:  2009-05-14       Impact factor: 5.742

10.  FibroScan, aspartate aminotransferase and alanine aminotransferase ratio (AAR), aspartate aminotransferase to platelet ratio index (APRI), fibrosis index based on the 4 factor (FIB-4), and their combinations in the assessment of liver fibrosis in patients with hepatitis B.

Authors:  Deping Ding; Hongbing Li; Ping Liu; Lingli Chen; Jian Kang; Yinhua Zhang; Deqiang Ma; Yue Chen; Jie Luo; Zhongji Meng
Journal:  Int J Clin Exp Med       Date:  2015-11-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.